ClinicalTrials.gg
TerminatedNCT03153813CHILI-OBUpdated Apr 17, 2019

Capsaicin Patches In Knee Osteoarthritis In Obese Patients

A Phase 3 interventional study of capsaicin 8% patches (Qutenza) and Placebo patches in Pain, sponsored by Nadine ATTAL. Terminated at 1 site in France. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-04-17.

Sponsored by Nadine ATTAL · Phase 3, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 25 studies testing capsaicin in Pain — none open to participants now, none under way, none of them phase 3. Capsaicin · Pain.

Enrollment
16th of 21
22 · median 69
Started
2015
with 1 other
Phase 3
10 of 25
none open now
Registered
21st of 25
by date
Lead sponsor
1 of 25
Nadine ATTAL

Among the 25 studies testing capsaicin in Pain, this one is the 16th largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2015, is one of 10 in phase 3, and was the 21st registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

None of the 25 studies testing capsaicin in Pain is open now. The open studies under Pain, anywhere →

About capsaicin

Capsaicin: first FDA approval 2009 (QUTENZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 25 studies testing capsaicin in Pain as a file.
02

Study summary

To assess the efficacy and safety of high concentration capsaicin patches in pain due to osteoarthritis (OA) of the knee in patients with obesity

Read the detailed description

Osteoarthritis is one of the leading causes of pain and disability. In France osteoarthritis of the knee, the most common form of osteoarthritis has been recently estimated to affect 4.7 % of men and 2.5 % of women .

One particularly exposed population to osteoarthritis is represented by obese patients. Obesity, defined as a body mass index (BMI) above 30 kg/m², is considered to be one of the most important risk factors for osteoarthritis (OA) in knees. Numerous longitudinal studies show a strong association between obesity, and radiographic knee OA, e.g. in the Framingham Study, the Chingford Study, the Baltimore Longitudinal Study of Aging, the John Hopkins Precursors Study, and in longitudinal studies in UK and the Netherlands. Thus, the WHO initiative on counteracting obesity also accepts OA as a consequence of obesity . Each BMI increase by 1 kg/m² is associated with a 15% increased risk of OA. A number of recent studies involving the association between obesity and knee osteoarthritis have since been published. A large, population-based prospective study (n = 823) conducted by Toivanen et al. with a follow-up of 22 years found that the risk for knee osteoarthritis was 7 times greater for people with BMI ≥30 compared to the control of people with BMI \<25. A prospective cohort study of the Norwegian population by Grotle et al. (10) that followed 1,675 patients reported that BMI >30 was significantly associated with osteoarthritis of the knee, with odds ratio of 2.81, and 95% CI of 1.32-5.96. Lohmander et al. found that in a large cohort study of 27,960 patients from the Swedish population, the relative risk for knee osteoarthritis (fourth quartile compared to first quartile) was 8.1, with a 95% CI of 5.3-12.4. Finally, a case-control study from Holliday et al. with 1,042 knee osteoarthritis patients and 1,121 matched controls reported that the adjusted odds ratio for knee osteoarthritis in patients with BMI >30 was 7.48 with 95% CI of 5.45-10.27.

Pain is one of the major comorbid conditions that may preclude effective weight management in these patients, particularly with regards to physical activity, since pain increases with effort and movement. Obese patients generally receive oral analgesics, such as weak opioids or tramadol, but due to a number of associated comorbidities, they generally do not tolerate, or have contraindications to, centrally acting analgesics. Furthermore an increasing number of obese patients are managed by malabsorbtive bariatric surgical procedures, exposing them at risk for inefficacity by oral analgesics, in regards to the malabsorptive effect.

Therefore alternative therapies, and in particular topical treatments, may be indicated in these patients as these drugs have less systemic side effects. The use of such treatments in patients with obesity should contribute to facilitate rehabilitation and hence contribute to weight loss, which may further help to reduce pain.

One promising topical treatment is represented by capsaicin. Capsaicin is an agonist of the transient receptor potential vanilloid 1 (TRPV1), a non-selective cation channel. It is well established that capsaicin applied in high concentration to the skin can cause initial nociceptor sensitization through its agonistic effects on TRPV1 receptors then subsequently acts in the skin to attenuate cutaneous hypersensitivity and reduce pain by a process best described as "defunctionalisation" of nociceptor fibres (e.g. temporary loss of membrane potential, inability to transport neurotrophic factors leading to altered phenotype, and reversible retraction of epidermal and dermal nerve fibre terminals). Evidence suggests that the utility of topical capsaicin may extend beyond painful peripheral neuropathies, and that this treatment may be particularly relevant in patients with osteoarthritis pain. Thus TRPV1 is mainly expressed by nociceptive neurons in dorsal root and trigeminal ganglia. However, there is increasing evidence that TRPV1 is also expressed in various cell types including synovial fibroblasts (SF) from patients with symptomatic osteoarthritis (OA) and thus may play a role in non-neuronal mechanisms that might modulate nociception in symptomatic osteoarthritis.

An additional effect of high concentration of capsaicin, which does not involve TRPV1, is a direct inhibition of mitochondrial respiration. Furthermore, by using the approach of patch-clamp, capsaicinoids (capsaicin and dihydrocapsaicin) have been shown to reversibly inhibit the currents of T-type voltage-dependent Ca2+channels, suggesting the effect of capsaicinoids on pain relief may also be related to the inhibition of T-type Ca2+ channels.

Capsaicin is metabolized rapidly by several cytochrome enzymes present in human liver, but in vitro studies shows that its metabolism in human skin is quite low. Capsaicin reside at the site of action (i.e. skin) relatively unchanged, whereas capsaicin which is transdermally absorbed is rapidly eliminated and does not have any systemic effect.

To date, repeated applications of low dose capsaicin cream at different concentrations (0.0125 to 0.25 %) have been found moderately effective in OA of the knee or hand, based on the basis of six double or single blind trials with sample sizes ranging from 14 to 200 patients. However repeated applications of capsaicin cream are difficult on the long term particularly because of the burning sensation induced by the cream and the necessity to repeat applications several times per day.

Recently high concentration capsaicin patches (8%) (Qutenza) have been developed for the treatment of peripheral neuropathic pain. These treatments induce long lasting analgesic effects in these conditions lasting up to an average of 3 months after a 30 to 60 minutes application. The burning side effect related to the application of the patch is rapidly reversible and very few severe side effects have been reported with this procedure.

If the primary cause of chronic musculoskeletal pain lies deep within joints and topical capsaicin does not provide substantial transdermal delivery, then the apparent efficacy of topical capsaicin in lower back pain and OA could be postulated to be by CNS modulatory mechanisms. Another possibility is that alterations in, or sensitization of, cutaneous nociceptors could be a contributing factor. Such alterations might be driven by unusually high concentrations of cytokines or growth factors in joints which could either diffuse some distance away from the primary site of inflammation or promote excitatory phenotypes in nearby collateral axons. Furthermore there is increasing evidence that TRPV1 expression is not limited to primary afferent neurons but that the receptor is expressed in various cell types throughout the body. TRPV1 is present in synovial fibroblasts from symptomatic OA and RA (rheumatoid arthritis) patients and the receptor can be activated by stimulation with the vanilloid capsaicin. It is very likely that capsaicin stimulation does not only induce IL-6 production but also results in the release of other signalling molecules that may transfer the information to other non-neuronal or neuronal cells and thereby contribute to a modulation of nociception in the inflamed joint.

Based on the mechanisms described above, there are reasons to believe that Qutenza may also be effective in osteoarthritis pain. To date, there are strictly no data regarding potential efficacy and safety of this treatment in osteoarthritis pain in obese patients

03

Conditions studied

  • Pain

Keywords

  • pain
  • knee osteoarthritis
  • obesity
  • capsaicin
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Enrolled patients will be males or females,
  • aged over 18 years,
  • have pain for at least 3 months due to mild to moderate osteoarthritis of the knee (meeting American College of Rheumatology clinical and radiographic criteria), of at least moderate intensity (pain intensity score over the last 24 hours before enrolment ≥ 4/10),
  • with a above 30 kg/m²
  • and no other pain conditions accounting for their disability.
  • The skin will be intact and no blessed.
  • All female patients should take during all study and at least 30 days after closer.
  • All patients must sign .
  • All patients will be recruited from the Department of Nutrition, Ambroise Paré University Hospital and treatment will be given during a dedicated day care clinic.

Exclusion criteria

Exclusion Criteria:

  • Patients necessitating surgery,
  • with relative to capsaicin patches, particularly with unstable hypertension or cardiac condition,
  • past history of capsaicin use will not be included.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Drug

    Up to 4 patches to cover a surface of 1200 cm2 will be applied to the painful area depending on the surface of pain during 60 minutes : capsaicin 8% patches (Qutenza)

    Drug: capsaicin 8% patches (Qutenza)

  • Placebo comparator
    Placebo

    Up to 4 patches will be applied to the painful area depending on the surface of pain during 60 minutes : placebo

    Other: Placebo patches

Interventions

06

What researchers measure

Primary outcomes

  1. Effects on self reported average pain intensity on pain diaries throughout the study (on NRS from 0 to 10)

    The primary outcome measure will be the reduction of average pain intensity as assessed by the patients daily using a pain diary throughout the 3 months of the study. The comparison will be made with baseline pain values started 7 days before the treatment.

    Time frame: Over the 3 months of the study

Secondary outcomes

  1. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain, function and stiffness

    WOMAC pain and function index

    Time frame: at each follow up period 1, 2 and 3 months as compared to baseline values

  2. safety as assessed by side effects during and after application

    Time frame: during and immeditaly after application and at each follow up period 1, 2 and 3 months

07

Study locations

1 site
  • Hospital Ambroise Paré, Nutrition Department
    Boulogne-Billancourt, 92100, France
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2015, a primary completion of Dec 2017 and a completion of Dec 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2015
First posted
May 15, 2017
Start
Jul 2015
Primary completionActual
Dec 2017
CompletionActual
Dec 2018
Last update
Apr 17, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03153813
Lead sponsor
Nadine ATTAL
Responsible party
Nadine ATTAL (Co-investigator, Hospital Ambroise Paré Paris) — Sponsor-investigator
First posted
May 15, 2017
Start date
Jul 2015
Primary completion
Dec 2017
Completion
Dec 2018
Last update
Apr 17, 2019

Study contacts

Claire Carette
principal investigator · Hospital Ambroise Pare Paris

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Capsaicin

Start the discussion